Pacific Edge Ltd PEB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NZD 0.09
- Day Range
- NZD 0.09–0.10
- 52-Week Range
- NZD 0.05–0.50
- Bid/Ask
- NZD 0.10 / NZD 0.10
- Market Cap
- NZD 79.45 Mil
- Volume/Avg
- 145,348 / 425,266
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 34
- Website
- https://www.pacificedgedx.com
Valuation
|
Metric
|
PEB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.13 |
Price/Sales | 3.04 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PEB
|
|---|---|
Quick Ratio | 9.54 |
Current Ratio | 10.01 |
Interest Coverage | −1,045.46 |
Quick Ratio
PEB
Profitability
|
Metric
|
PEB
|
|---|---|
Return on Assets (Normalized) | −35.23% |
Return on Equity (Normalized) | −38.61% |
Return on Invested Capital (Normalized) | −37.89% |
Return on Assets
PEB
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Qyctdgyh | Nkhj | $227.9 Bil | |
DHR
| Danaher Corp | Ypkyqhlpb | Smfnzrn | $196.2 Bil | |
A
| Agilent Technologies Inc | Rdbzqrphb | Hknk | $45.2 Bil | |
IDXX
| IDEXX Laboratories Inc | Tnvfwfqww | Cmttth | $44.7 Bil | |
IQV
| IQVIA Holdings Inc | Ktzsrnzd | Nphzsl | $42.8 Bil | |
MTD
| Mettler-Toledo International Inc | Ycnrcxzbc | Rgfbwv | $32.7 Bil | |
ICLR
| Icon PLC | Qvqlwgwwc | Fqpbhm | $26.1 Bil | |
WAT
| Waters Corp | Pylbzwzfp | Klgy | $21.4 Bil | |
ILMN
| Illumina Inc | Srfjdnbs | Jfpbw | $18.2 Bil | |
LH
| Laboratory Corp of America Holdings | Ymxmytsqvc | Tpjcywl | $18.0 Bil |